Novel agents including proteasome inhibitors and immunomodulatory drugs are now
routinely utilized as part of the induction regimen before transplantation and this has …

In the modern era of multiple myeloma therapeutics, proteasome inhibitor (PI) and
immunomodulatory drugs (IMiDs) have replaced chemotherapy regimens for newly …

Optimizing consolidation treatment in transplant‐eligible newly diagnosed multiple myeloma
patients in order to improve efficacy and bone‐related outcomes is intriguing. We conducted …

Abstract Unlike IgG monoclonal proteins (MCPs), IgA MCP quantification is unreliable due to
beta-migration of IgA MCPs on serum protein electrophoresis (SPEP). The utility of …

Serum protein electrophoresis (SPE) and immunofixation is commonly used to screen for
plasma cell dyscrasias. Interpretation of these tests is qualitative by nature and can yield …

Novel agents including immunomodulatory drugs and proteasome inhibitors incorporated
into induction regimens and subsequently followed by autologous stem cell transplantation …

A regimen of escalating doses of thalidomide, in combination with bortezomib and high-
dose melphalan (mel/vel/thal), was evaluated as a conditioning regimen for autologous stem …

For young patients, eligible to high dose therapy, a first line treatment including induction
before and consolidation after peripheral blood stem cells transplant is recommended …

Chez les sujets jeunes, éligibles au traitement intensif, un traitement d'induction avant
l'autogreffe de cellules souches et un autre, de consolidation, après, sont recommandés en …

Inclusion of new active drugs, such as IMiDs, proteasome inhibitors and soon the
monoclonal antibodies, in first-line therapy has and will significantly enhance the response …